ATE155813T1
(de)
*
|
1989-05-19 |
1997-08-15 |
Genentech Inc |
Her2 extrazellulare domäne
|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
US5578482A
(en)
*
|
1990-05-25 |
1996-11-26 |
Georgetown University |
Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
|
US6824777B1
(en)
*
|
1992-10-09 |
2004-11-30 |
Licentia Ltd. |
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
US5776755A
(en)
*
|
1992-10-09 |
1998-07-07 |
Helsinki University Licensing, Ltd. |
FLT4, a receptor tyrosine kinase
|
US6107046A
(en)
*
|
1992-10-09 |
2000-08-22 |
Orion Corporation |
Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
|
US5811098A
(en)
*
|
1992-11-24 |
1998-09-22 |
Bristol-Myers Squibb Company |
Antibodies to HER4, human receptor tyrosine kinase
|
EP0706573A1
(de)
*
|
1993-07-09 |
1996-04-17 |
The Institute Of Cancer Research |
Protein - Tyrosinkinase und Ligande davon
|
DE69435103D1
(de)
*
|
1993-10-27 |
2008-07-10 |
Univ Columbia |
Methode zur Bildung einer subtrahierten cDNA Bank und ihre Verwendung
|
US5518885A
(en)
*
|
1994-04-19 |
1996-05-21 |
The United States Of America As Represented By The Department Of Health & Human Services |
ERBB2 promoter binding protein in neoplastic disease
|
US5985598A
(en)
*
|
1994-10-27 |
1999-11-16 |
Thomas Jefferson University |
TCL-1 gene and protein and related methods and compositions
|
US7175995B1
(en)
|
1994-10-27 |
2007-02-13 |
Thomas Jefferson University |
TCL-1 protein and related methods
|
US5635351A
(en)
*
|
1995-03-14 |
1997-06-03 |
The Regents Of The University Of California |
Genetic gain and loss in gliomas
|
US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
PT896586E
(pt)
*
|
1996-03-27 |
2007-01-31 |
Genentech Inc |
Anticorpos de erbb3
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
DE69740038D1
(de)
|
1996-07-12 |
2010-12-16 |
Genentech Inc |
|
JP4382879B2
(ja)
*
|
1996-07-12 |
2009-12-16 |
ジェネンテック・インコーポレーテッド |
ガンマ―ヘレグリン
|
US5710137A
(en)
*
|
1996-08-16 |
1998-01-20 |
The Trustees Of Columbia University In The City Of New York |
Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
US6387638B1
(en)
|
1997-02-10 |
2002-05-14 |
Genentech, Inc. |
Heregulin variants
|
US6136558A
(en)
*
|
1997-02-10 |
2000-10-24 |
Genentech, Inc. |
Heregulin variants
|
EP1690927A1
(de)
*
|
1997-04-30 |
2006-08-16 |
Hans Klingemann |
Natürliche Killerzelllinien und Verfahren zu ihrer Verwendung
|
US7052692B1
(en)
|
1997-09-02 |
2006-05-30 |
Advanced Research & Technology Institute |
Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
|
IL135607A0
(en)
|
1997-10-29 |
2001-05-20 |
Genentech Inc |
Wnt-1 inducible genes
|
US6387657B1
(en)
|
1997-10-29 |
2002-05-14 |
Genentech, Inc. |
WISP polypeptides and nucleic acids encoding same
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
US20010023241A1
(en)
*
|
1998-02-04 |
2001-09-20 |
Sliwkowski Mark X. |
Use of heregulin as a growth factor
|
EP1941905A1
(de)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
|
ATE489108T1
(de)
*
|
1998-10-09 |
2010-12-15 |
Vegenics Ltd |
Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
|
ES2307505T3
(es)
*
|
1999-04-06 |
2008-12-01 |
Genentech, Inc. |
Utilizacion de ligandos receptores de erbb en el tratamiento de la diabetes.
|
CA2370466C
(en)
|
1999-06-25 |
2011-02-08 |
Sharon Erickson |
Methods of treatment using anti-erbb antibody-maytansinoid conjugates
|
AUPQ105799A0
(en)
*
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
MXPA01013395A
(es)
*
|
1999-06-25 |
2003-09-04 |
Genentech Inc |
Tratamiento de cancer de prostata con anticuerpos anti-erbb2.
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
EP1189641B1
(de)
|
1999-06-25 |
2009-07-29 |
Genentech, Inc. |
Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
SI1210115T1
(sl)
|
1999-08-27 |
2009-12-31 |
Genentech Inc |
Doziranja za zdravljenje s protitelesi proti ErbB2
|
US7390632B2
(en)
*
|
1999-09-30 |
2008-06-24 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
US7892541B1
(en)
|
1999-09-30 |
2011-02-22 |
Tumor Biology Investment Group, Inc. |
Soluble epidermal growth factor receptor isoforms
|
EP2289549A3
(de)
|
1999-10-01 |
2011-06-15 |
Immunogen, Inc. |
Immunokonjugate für Krebsbehandlung
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
WO2001083781A2
(en)
*
|
2000-04-28 |
2001-11-08 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
DE60139768D1
(de)
*
|
2000-05-19 |
2009-10-15 |
Genentech Inc |
Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine k
|
CN1204142C
(zh)
*
|
2000-06-01 |
2005-06-01 |
冯宝章 |
反基因V-erbB寡核苷酸及其应用
|
US6277640B1
(en)
|
2000-07-31 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Her-3 expression
|
US20020119148A1
(en)
*
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
US7344829B2
(en)
*
|
2000-11-03 |
2008-03-18 |
Board Of Regents, The University Of Texas System |
Methods for detecting the efficacy of anticancer treatments
|
DE60219419T2
(de)
*
|
2001-01-19 |
2007-08-16 |
Ludwig Institute For Cancer Research |
Flt4 (vegfr-3) als ein ziel für krebsdarstellung und anti-krebs-behandlung
|
EP1228766A1
(de)
*
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 Phosphorylierung durch HER3 induziert Tumorinvasion
|
WO2002081649A2
(en)
*
|
2001-04-06 |
2002-10-17 |
The Trustees Of The University Of Pennsylvania |
ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
|
EP1385962A2
(de)
*
|
2001-05-02 |
2004-02-04 |
Bayer HealthCare AG |
Menschliche prolyl 4-hydroxylasen
|
US7612042B2
(en)
*
|
2001-05-31 |
2009-11-03 |
Tumor Biology Investment Group, Inc. |
Methods for inhibiting heregulin and treating cancer
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
US7745398B2
(en)
*
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
DE10131187C2
(de)
*
|
2001-06-28 |
2003-06-18 |
Infineon Technologies Ag |
Belichtungsmaske mit reparierter Blindstruktur
|
US7125680B2
(en)
|
2001-07-27 |
2006-10-24 |
The Regents Of The University Of California |
Methods and materials for characterizing and modulating interaction between heregulin and HER3
|
EP1283053A1
(de)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitore der HER3 Aktivität
|
AU2002326910A1
(en)
*
|
2001-09-14 |
2003-04-01 |
Incyte Genomics, Inc. |
Receptors and membrane-associated proteins
|
JP2003110360A
(ja)
*
|
2001-09-28 |
2003-04-11 |
Seiko Epson Corp |
電圧制御型発振器、受信装置および通信装置
|
JP4660094B2
(ja)
*
|
2002-03-26 |
2011-03-30 |
ゼンサン (シャンハイ) サイ−テク. リミテッド |
新生物を治療するためのErbB3に基づく方法および組成物
|
WO2005117986A2
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody drug conjugates and methods
|
US7402397B2
(en)
|
2002-05-21 |
2008-07-22 |
Monogram Biosciences, Inc. |
Detecting and profiling molecular complexes
|
US20040229380A1
(en)
*
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB heterodimers as biomarkers
|
US20040229294A1
(en)
*
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB surface receptor complexes as biomarkers
|
JP4405916B2
(ja)
|
2002-05-23 |
2010-01-27 |
トラスティース・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
Fasペプチド模倣体およびその使用
|
CA2490758C
(en)
|
2002-07-15 |
2014-09-23 |
Genentech, Inc. |
Dosage form of recombinant humanized monoclonal antibody 2c4
|
TWI229650B
(en)
*
|
2002-11-19 |
2005-03-21 |
Sharp Kk |
Substrate accommodating tray
|
US20040258685A1
(en)
*
|
2002-11-21 |
2004-12-23 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
|
CA2521077A1
(en)
|
2003-04-01 |
2004-10-28 |
Monogram Biosciences, Inc. |
Erbb surface receptor complexes as biomarkers
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
US20050239088A1
(en)
*
|
2003-05-16 |
2005-10-27 |
Shepard H M |
Intron fusion proteins, and methods of identifying and using same
|
US7402398B2
(en)
*
|
2003-07-17 |
2008-07-22 |
Monogram Biosciences, Inc. |
Measuring receptor homodimerization
|
AU2004267420A1
(en)
*
|
2003-08-11 |
2005-03-03 |
Monogram Biosciences, Inc. |
Detecting and profiling molecular complexes
|
WO2005037071A2
(en)
*
|
2003-10-14 |
2005-04-28 |
Monogram Biosciences, Inc. |
Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
|
PT2489364E
(pt)
|
2003-11-06 |
2015-04-16 |
Seattle Genetics Inc |
Compostos de monometilvalina conjugados com anticorpos
|
WO2005099756A2
(en)
*
|
2004-04-08 |
2005-10-27 |
Agus David B |
ErbB ANTAGONISTS FOR PAIN THERAPY
|
WO2005113596A2
(en)
*
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
SV2006002143A
(es)
*
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
KR20180091967A
(ko)
|
2004-07-22 |
2018-08-16 |
제넨테크, 인크. |
Her2 항체 조성물
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US7939267B2
(en)
*
|
2004-11-04 |
2011-05-10 |
Laboratory Corporation Of America Holdings |
Detection of activation of endothelial cells as surrogate marker for angiogenesis
|
EP1825001A2
(de)
*
|
2004-12-07 |
2007-08-29 |
Genentech, Inc. |
Auswahl von patienten zur therapie mit einem her-inhibitor
|
CN101141981A
(zh)
*
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
KR20070100968A
(ko)
*
|
2005-02-09 |
2007-10-15 |
제넨테크, 인크. |
매트릭스 메탈로프로테아제 길항제를 사용한, her2박리의 억제
|
DK1850874T3
(da)
|
2005-02-23 |
2013-11-11 |
Genentech Inc |
Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
|
WO2006096861A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
MX2009001291A
(es)
|
2006-08-04 |
2009-03-10 |
Astrazeneca Ab |
Anticuerpos para erbb2.
|
EP2518508A1
(de)
|
2006-11-28 |
2012-10-31 |
U3 Pharma GmbH |
Aktiviertes HER3 als Marker zur Vorhersage der Therapieeffizienz
|
JP5564266B2
(ja)
*
|
2007-02-16 |
2014-07-30 |
メリマック ファーマシューティカルズ インコーポレーティッド |
Erbb3に対する抗体およびその使用
|
KR20090115980A
(ko)
|
2007-03-02 |
2009-11-10 |
제넨테크, 인크. |
낮은 her3 발현을 기초로 한 her 이량체화 억제제에 대한 반응 예측
|
CA2680237C
(en)
|
2007-03-27 |
2018-11-06 |
Sea Lane Biotechnologies, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
ES2417148T3
(es)
|
2007-06-08 |
2013-08-06 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
CA2706763C
(en)
*
|
2007-11-27 |
2013-07-30 |
Laboratory Corporation Of America Holdings |
Enhanced method for detecting and/or quantifying an analyte in a sample
|
US10416162B2
(en)
*
|
2007-12-20 |
2019-09-17 |
Monogram Biosciences, Inc. |
Her2 diagnostic methods
|
SI2229369T1
(sl)
*
|
2008-01-18 |
2016-11-30 |
Natco Pharma Limited |
Derivati 6,7-dialkoksi kinazolina, uporabni za zdravljenje motenj, povezanih z rakom
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
KR20210131473A
(ko)
|
2008-03-18 |
2021-11-02 |
제넨테크, 인크. |
항-her2 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
WO2009157919A1
(en)
*
|
2008-06-23 |
2009-12-30 |
Tumor Biology Investment Group, Inc. |
SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER
|
BRPI0917871A2
(pt)
*
|
2008-08-15 |
2017-06-20 |
Merrimack Pharmaceuticals Inc |
agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
|
CA2764386C
(en)
|
2008-12-01 |
2018-05-01 |
Laboratory Corporation Of America Holdings |
P95-her2 antibodies and uses thereof
|
US8349574B2
(en)
*
|
2009-01-15 |
2013-01-08 |
Laboratory Corporation Of America Holdings |
Methods of determining patient response by measurement of Her-3
|
AU2010226453B2
(en)
|
2009-03-20 |
2013-11-21 |
Genentech, Inc. |
Bispecific anti-HER antibodies
|
EP2425009A4
(de)
*
|
2009-04-29 |
2013-01-23 |
Trellis Bioscience Llc |
Verbesserte antikörper für immunreaktionen mit heregulin-gekoppeltem her3
|
JP2012526839A
(ja)
|
2009-05-13 |
2012-11-01 |
シー レーン バイオテクノロジーズ, エルエルシー |
インフルエンザウイルスに対する中和分子
|
SG176073A1
(en)
|
2009-05-29 |
2011-12-29 |
Hoffmann La Roche |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
US9050341B2
(en)
|
2009-07-14 |
2015-06-09 |
Natco Pharma Limited |
Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
|
AU2010306774A1
(en)
|
2009-10-14 |
2012-05-03 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
|
CN102812045B
(zh)
|
2009-11-13 |
2018-04-13 |
第一三共欧洲有限公司 |
用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法
|
JP6184695B2
(ja)
|
2009-12-04 |
2017-08-23 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体、抗体アナログ、組成物、及び方法
|
JP5680671B2
(ja)
|
2009-12-22 |
2015-03-04 |
ロシュ グリクアート アーゲー |
抗her3抗体及びその使用
|
MX344355B
(es)
|
2010-03-11 |
2016-12-14 |
Merrimack Pharmaceuticals Inc * |
Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal.
|
ES2566602T3
(es)
|
2010-04-09 |
2016-04-14 |
Aveo Pharmaceuticals, Inc. |
Anticuerpos anti-ErbB3
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
US8741288B2
(en)
*
|
2010-07-07 |
2014-06-03 |
Chang Gung Medical Foundation, Linkou Branch |
Protein markers for detecting liver cancer and method for identifying the markers thereof
|
BR112013004012B1
(pt)
|
2010-08-20 |
2021-03-23 |
Novartis Ag |
Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
KR20140044796A
(ko)
|
2011-03-11 |
2014-04-15 |
메리맥 파마슈티컬즈, 인크. |
호르몬 무반응 유방암의 치료에서 egfr-패밀리 수용체의 저해제의 용도
|
SI2699602T1
(sl)
|
2011-04-19 |
2017-06-30 |
Merrimack Pharmaceuticals, Inc. |
Bispecifična protitelesa anti-igf-1r in anti-erbb3
|
WO2012156309A1
(en)
|
2011-05-13 |
2012-11-22 |
Millegen |
Antibodies against her3
|
JP6468838B2
(ja)
|
2011-05-19 |
2019-02-13 |
ラボラトリー コーポレイション オブ アメリカ ホールディングス |
癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法
|
JPWO2012176779A1
(ja)
|
2011-06-20 |
2015-02-23 |
協和発酵キリン株式会社 |
抗erbB3抗体
|
WO2013016714A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies |
Sur-binding proteins against erbb3
|
CN104024432B
(zh)
|
2011-08-31 |
2017-02-22 |
基因泰克公司 |
诊断性标志物
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
EA028879B1
(ru)
|
2011-09-30 |
2018-01-31 |
Ридженерон Фармасьютикалз, Инк. |
АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
|
AU2012318541B2
(en)
|
2011-10-06 |
2018-04-12 |
Aveo Pharmaceuticals, Inc. |
Predicting tumor response to anti-ERBB3 antibodies
|
KR20230028585A
(ko)
|
2011-10-14 |
2023-02-28 |
제넨테크, 인크. |
Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품
|
RU2620068C2
(ru)
|
2011-11-23 |
2017-05-22 |
МЕДИММЬЮН, ЭлЭлСи |
Связывающие молекулы, специфичные по отношению к her3, и их применения
|
US20130195870A1
(en)
|
2011-11-30 |
2013-08-01 |
Genentech, Inc. |
ERBB3 Mutations In Cancer
|
SG11201402783YA
(en)
|
2011-12-05 |
2014-06-27 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
EP2788382A2
(de)
|
2011-12-05 |
2014-10-15 |
Novartis AG |
Antikörper für epidermalen wachstumsfaktor-rezeptor 3 (her3) gegen domäne ii von her3
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
EP2793940B1
(de)
|
2011-12-22 |
2018-11-14 |
i2 Pharmaceuticals, Inc. |
Surrogatbindungsproteine
|
ES2842201T3
(es)
|
2012-02-23 |
2021-07-13 |
Daiichi Sankyo Europe Gmbh |
Inhibidor de HER3 para modulación de radiosensibilidad
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック, インコーポレイテッド |
Her3阻害剤に関する診断及び治療
|
CA2868516A1
(en)
|
2012-04-02 |
2013-10-10 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
|
WO2014083178A1
(en)
|
2012-11-30 |
2014-06-05 |
F. Hoffmann-La Roche Ag |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
US9180185B2
(en)
|
2013-01-11 |
2015-11-10 |
Hoffman-La Roche Inc. |
Combination therapy of anti-HER3 antibodies
|
EP2954068B8
(de)
|
2013-02-05 |
2018-10-31 |
Pierian Holdings, Inc. |
Wirkstoffauswahl für eine therapie gegen nicht-kleinzelligen lungenkrebs
|
WO2014124487A1
(en)
|
2013-02-18 |
2014-08-21 |
Vegenics Pty Limited |
Ligand binding molecules and uses thereof
|
JP6402173B2
(ja)
|
2013-04-05 |
2018-10-10 |
ラボラトリー コーポレイション オブ アメリカ ホールディングス |
Her3の検出に基づく癌の診断、予後予測、および処置を容易にするためのシステムおよび方法
|
US10239951B2
(en)
|
2013-05-08 |
2019-03-26 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
EP3087394A2
(de)
|
2013-12-27 |
2016-11-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarkerprofile zur vorhersage der ergebnisse einer krebstherapie mit erbb3-inhibitoren und/oder chemotherapien
|
CN107002119A
(zh)
|
2014-03-24 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
|
TWI745021B
(zh)
|
2014-04-10 |
2021-11-01 |
日商第一三共股份有限公司 |
抗her3抗體-藥物結合物之製造方法
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
EP3169708B1
(de)
|
2014-07-16 |
2019-03-20 |
Dana-Farber Cancer Institute Inc. et Al. |
Her3-inhibition bei serösem low-grade-ovarialkarzinom
|
EP3169354A4
(de)
|
2014-07-17 |
2018-06-13 |
Brian J. Czerniecki |
Identifikation von immunogenen mhc-klasse-ii-peptiden für immunbasierte therapie
|
EP3229803B1
(de)
|
2014-12-12 |
2020-01-29 |
Massachusetts General Hospital |
Behandlung von brustkrebsgehirnmetastasen
|
EP3303398A1
(de)
|
2015-05-29 |
2018-04-11 |
Merrimack Pharmaceuticals, Inc. |
Kombinationskrebstherapien
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
US11173213B2
(en)
|
2015-06-29 |
2021-11-16 |
Daiichi Sankyo Company, Limited |
Method for selectively manufacturing antibody-drug conjugate
|
EP3325005A4
(de)
*
|
2015-07-17 |
2019-03-27 |
Brian J. Czerniecki |
Identifikation von immunogenen mhc-klasse-ii-peptiden für immunbasierte therapie
|
US20170233491A1
(en)
|
2016-01-19 |
2017-08-17 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment
|
MX2018011054A
(es)
|
2016-03-15 |
2019-01-21 |
Merrimack Pharmaceuticals Inc |
Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
EP3552626A4
(de)
|
2016-12-12 |
2020-06-10 |
Daiichi Sankyo Company, Limited |
Kombination aus antikörper-wirkstoff-konjugat und immun-checkpoint-inhibitor
|
KR102313262B1
(ko)
|
2016-12-28 |
2021-10-14 |
제넨테크, 인크. |
진행성 her2 발현 암의 치료
|
CN110382535A
(zh)
|
2017-01-17 |
2019-10-25 |
第一三共株式会社 |
抗-gpr20抗体以及抗-gpr20抗体-药物缀合物
|
JP6741875B2
(ja)
|
2017-01-17 |
2020-08-19 |
ジェネンテック, インコーポレイテッド |
皮下her2抗体製剤
|
KR102417583B1
(ko)
|
2017-03-02 |
2022-07-07 |
제넨테크, 인크. |
Her2-양성 유방암 어쥬번트 치료
|
KR20190140952A
(ko)
|
2017-04-24 |
2019-12-20 |
제넨테크, 인크. |
막관통 및 인접막 도메인에서의 erbb2/her2 돌연변이
|
TWI794230B
(zh)
|
2017-05-15 |
2023-03-01 |
日商第一三共股份有限公司 |
抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
|
CN110831624B
(zh)
*
|
2017-06-02 |
2024-04-16 |
埃特彼塞斯公司 |
涉及her抗原的用于肿瘤疫苗接种和免疫疗法的组合物及方法
|
SG11202001514XA
(en)
|
2017-08-31 |
2020-03-30 |
Daiichi Sankyo Co Ltd |
Novel method for producing antibody-drug conjugate
|
BR112020003646A2
(pt)
|
2017-08-31 |
2020-09-01 |
Daiichi Sankyo Company, Limited |
cristais, métodos para produção de cristais e de um conjugado anticorpo-fármaco, e, sal.
|
EP4249002A3
(de)
|
2018-05-18 |
2023-11-22 |
Daiichi Sankyo Co., Ltd. |
Conjugue agent cytotoxique et anticorps anti-muc1-exatecan
|
KR20230030621A
(ko)
|
2020-06-29 |
2023-03-06 |
제넨테크, 인크. |
퍼투주맙 + 트라스투주맙 고정 용량 조합
|
EP4180061A1
(de)
|
2021-11-10 |
2023-05-17 |
Nerviano Medical Sciences S.r.l. |
Linker-reagenzien für anthracyclinderivate, antikörper-arznemittelkonjugate und verfahren
|